October 31st 2024
A new laboratory will be built in Oss, while additional capacity and capabilities will be added to the Bioanalytical Center of Excellence in Assen.
EC Approves Tecentriq Combination Therapy for Metastatic Triple-Negative Breast Cancer
September 3rd 2019Roche revealed that the European Commission has approved the combination of Tecentriq (atezolizumab) with Abraxane for the treatment of adult patients with PD-L1-positive, metastatic triple-negative breast cancer.